Table 2 Conditioning regimens before allo-HSCT (n = 89)

TBI 8 Gy, Cyclophosphamide, Fludarabine (myeloablative conditioning)

8 Gy TBI (four 2 Gy doses on two consecutive days, d -8, d -7), Cyclophosphamide 2 × 60 mg/kg (d -4, d -3), Fludarabine 3 × 30 mg/m² (d -6, d -5, d -4)

42 (47.2%)

FLAMSA-RIC, TBI 4 Gy, Cyclophosphamide (reduced-intensity conditioning)

FLAMSA regimen (d -12 to d -9), Fludarabine 4 × 30 mg/m², HD-Ara-C 4 × 2000 mg/m², Amsacrine 4 × 100 mg/m². Reduced intensity conditioning regimen after 3 days of rest: 4 Gy TBI on d -5 (two 2 Gy doses), Cyclophosphamide (2 × 40 mg/kg for MRD or 2 × 60 mg/kg for MUD, MMRD or MMUD) on d -4 to d -3,

Antithymocyte globulin (ATG) 10 mg/kg for MRD or 20 mg/kg for MUD, MMRD, MMUD from d -4 to d -2,

prophylactic donor lymphocyte infusions at day + 120 or 30 days after discontinuation of immunosuppression, 1–5 × 10⁶ CD3⁺cells/kg

31 (34.8%)

TBI 12 Gy, Cyclophosphamide (myeloablative conditioning)

12 Gy TBI (six 2 Gy doses, on three consecutive days, d -7 to d -5), Cyclophosphamide 2 × 60 mg/kg on 2 consecutive days (d -4, d -3)

11 (12.4%)

TBI 8 Gy, Fludarabine (myeloablative conditioning)

8 Gy TBI (four 2 Gy doses on 2 consecutive days, d -5 and d -4), Fludarabine 4 × 30 mg/m² (d -5 to d -2)

5 (5.6%)